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Objectives These analyses were designed to determine the incidence of major cardiovascular (CV) events and the natural
history of CV complications in patients with Fabry disease.
Background Fabry disease, a genetic disorder caused by deficiency of alpha-galactosidase A activity, is associated with CV
dysfunction.
Methods Major CV events (myocardial infarction, heart failure, or cardiac-related death) were analyzed in 2,869 Fabry Registry pa-
tients during the natural history period (i.e., before enzyme replacement therapy or among patients who never received
therapy). Multivariate logistic regression analyses were performed to identify significant predictors of CV events.
Results Eighty-three of 1,424 men (5.8%) and 54 of 1,445 women (3.7%) experienced CV events at mean ages of 45
and 54 years, respectively. Heart failure was the most common first CV event, reported by 50 men (3.5%) and
33 women (2.3%). Hypertension and left ventricular hypertrophy were the risk factors most strongly associated
with CV events. When these parameters were used as covariates in logistic regression analyses, the odds ratio
(OR) for hypertension in men was 7.8 (95% confidence interval [CI]: 2.1 to 28.6, p  0.0019), and the OR for
hypertension in women was 4.5 (95% CI: 1.6 to 12.3, p  0.0037). The OR for left ventricular hypertrophy was
4.8 in men (95% CI: 1.03 to 22.2, p  0.0463) and 8.2 in women (95% CI: 2.6 to 26.0, p  0.0003).
Conclusions Major CV events occurred in approximately 5% of Fabry Registry patients during the natural history period.
All patients with Fabry disease should be monitored for possible CV risk factors, particularly hypertension
and left ventricular hypertrophy. (J Am Coll Cardiol 2011;57:1093–9) © 2011 by the American College of
Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2010.11.018Fabry disease is an X-linked lysosomal storage disorder,
characterized by decreased or absent activity of lysosomal
alpha-galactosidase A. As a result of this enzyme deficiency,
globotriaosylceramide (GL-3) and other glycosphingolipids
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Vital organ function progres-
sively declines over time, putting
patients with Fabry disease at
risk of developing renal failure,
cardiovascular (CV) dysfunction,
and stroke (2–6).
The CV manifestations of
Fabry disease include hyperten-
sion, left ventricular hypertrophy
(LVH), rhythm and conduction
abnormalities, increased intima-
media thickness, valvular insuffi-
ciency, and ischemic heart dis-
ease (7–9). Over time, these
cardiac complications can progress to heart failure (HF),
myocardial infarction (MI), and life-threatening arrhyth-
mias (4,6,10). However, the incidence rate and predictors of
CV events in patients with Fabry disease are not well
known. Recent data suggest that women and, occasionally,
pediatric patients experience CV manifestations and events
(6,11). A better understanding of the CV complications of
Fabry disease is essential for identifying patients for risk
stratification and potential therapy. Therefore, we evaluated
major CV events and the risk factors associated with these
events in an international cohort of patients in the Fabry
Registry.
Methods
The Fabry Registry is an ongoing, observational database
that compiles clinical and laboratory data on an interna-
tional cohort of patients with Fabry disease. All patients
with Fabry disease are eligible to enroll, regardless of
whether they are receiving enzyme replacement therapy
(ERT) from any commercial source. Patients provide in-
formed consent through local institutional review boards/
ethics committees and may decline to participate or with-
draw consent at any time. Independent boards of advisors
recommend clinical and outcome variables that should be
collected. Treating physicians determine the actual fre-
quency of assessments according to the individualized needs
of the patients. Given the voluntary nature of reporting
data, some assessments of patients are not consistently
reported to the Fabry Registry. In addition, patient ages at
clinical assessments and time intervals between assessments
are variable.
Data analyses and statistics. Only data from untreated
Fabry Registry patients or data obtained before any ERT
was initiated (among patients who received treatment) were
included in these analyses. The period of data extended
from date of birth until last available follow-up record
before initiation of therapy for each patient. Cross-sectional
data were analyzed with SAS statistical software version 9.1
(SAS Institute, Inc., Cary, North Carolina) and summa-
Abbreviations
and Acronyms
CI  confidence interval
CV  cardiovascular
ERT  enzyme replacement
therapy
GL-3 
globotriaosylceramide
HF  heart failure
LVH  left ventricular
hypertrophy
MI  myocardial infarction
OR  odds ratiorized with descriptive statistics. dDefinition of CV, renal, and cerebrovascular events.
CV events were defined as MI, HF, or cardiac-related
death. Renal events were defined as renal dialysis or renal
transplantation. Cerebrovascular events were defined as
stroke. Clinical events were reported to the Fabry Registry
by treating physicians, on the basis of their medical judg-
ment, and were not independently adjudicated.
Analysis of risk factors. Clinical and medical history data
in the Fabry Registry were analyzed to determine how many
patients had reported various potential cardiac risk factors,
including left posterior wall thickness, interval between each
P- and R-wave (PR interval), hypertension, a history of
smoking, hypercholesterolemia, estimated glomerular filtra-
tion rate, urinary protein to creatinine ratio, and diabetes.
The Modification of Diet in Renal Disease equation was
used to estimate glomerular filtration rate (12).
Risk factors for experiencing a CV event were analyzed
through univariate and multivariate logistic regression mod-
els. For the multivariate model, the stepwise selection
method was used to determine the covariates that best fit
the model (13). Results of these analyses are expressed as
odds ratios (ORs) and corresponding 95% confidence inter-
vals (CIs). The Wald chi-square test was used to evaluate
statistical significance with an alpha-level of p  0.05. Age
at CV events and age at diagnosis were compared between
patient groups with the Student t test.
Results
As of October 3, 2008, the Fabry Registry had enrolled
2,869 patients. Among these, 137 patients (4.8%) had
experienced a major CV event during the natural history
period, including 83 of 1,424 men (5.8%) and 54 of 1,445
women (3.7%). As shown in Table 1, the mean age at first
CV event was 45.2 years in men and 53.6 years in women
(p 0.0001). Among both sexes, Fabry Registry patients who
had CV events were diagnosed at an older age than patients
who did not: mean 40.9 years versus 26.4 years in men (p 
.0001), and mean 48.3 years versus 32.8 years in women
p  0.0001). As shown in Figure 1, most men (72%)
xperienced their first CV event between the ages of 35 and
55 years, whereas most women (72%) experienced their
rst CV event between the ages of 45 and 65 years. Five
f 83 men (6.0%) and 1 of 54 women (1.9%) experienced a
V event before age 25.
Heart failure was the most common type of CV event
mong this cohort; 50 of 83 men (60%) and 33 of 54 women
61%) experienced HF. Thirty-eight of 83 men experienced
I (46%), and 22 of 54 women experienced MI (41%). Six
atients had CV events before the age of 25 years: 3 men
ith HF, 2 men with MI, and 1 woman with HF.
The incidence rates of first CV events in the overall Fabry
egistry natural history population are shown in Table 2.
abry men exhibited a higher incidence of CV events than
abry women within each age category, with the greatest
ifference occurring between the ages of 45 and 55 years.
CV eve
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March 1, 2011:1093–9 CV Events in Fabry DiseaseAmong both sexes, the incidence rates of CV events
progressively increased with age, reaching a maximum in
patients over the age of 65 years. Because there are relatively
few Fabry Registry patients over the age of 65 years, the
95% CIs associated with these incidence rates are wide
(Table 2).
Demographic and Clinical Characteristics of Fabry Registry PatientTable 1 Demographic and Clinical Characteristics of Fabry Reg
Characteristics
Men With
CV Events
(n  83)
Me
C
(n
Age at first CV event (yrs)
Mean (SD) 45.2 (11.15)*
Median (range) 46.9 (19.3–76.8)
Age at Fabry diagnosis (yrs)
n 83
Mean (SD) 40.9 (15.92)*† 26.4
Median (range) 40.3 (7.3–81.0) 24.4
Hypertension, n (%) 47/82, 57.3% 320/1
Hypercholesterolemia, n (%) 6/14, 42.9% 129/6
History of smoking, n (%) 34/76, 44.7% 274/1
Estimated GFR, ml/min/1.73 m2, mean  SD (n) 66 36.4 (36) 90
Urinary protein to urinary creatinine ratio, g/g,
mean  SD (n)
3.4 3.86 (15) 1.1
Left ventricular posterior wall thickness, mm,
mean  SD (n)
15.4 3.58 (30) 11.6
Patients with cardiovascular (CV) events are patients for whom recorded CV events occurred during
calculated on the basis of the number of patients who had data available within each category. The d
wall thickness12mm; estimated glomerular filtration rate (GFR)90mg/ml/min/1.73m2; urin
BP 130 mm Hg or a measured diastolic BP 80 mm Hg or having reported a medical history o
total cholesterol level200 mg/dl or low-density lipoprotein level130 mg/dl or having reported
the last natural history value obtained before first CV event of the patient or the last value available
had CV events versus women who had CV events, by Student t test. †p  0.001 for men who had
event versus women who did not have CV events, by Student t test.
Figure 1 Age at First CV Event in Fabry Registry Patients
Percentages of patients experiencing their first cardiovascular (CV) event (heart fa
shown. Numbers above the bars indicate the number of patients in each category
at the time of their first CV event.Various cardiac and renal characteristics of the subset of
Fabry Registry patients who experienced CV events are
shown in Figure 2. The majority of these patients exhibited
LVH (defined as left ventricular posterior wall thickness
12 mm) and hypertension (defined as systolic blood
pressure 130 mm Hg or diastolic blood pressure 80 mm
Patients
out
ts
41)
Women With
CV Events
(n  54)
Women Without
CV Events
(n  1,391)
All Patients
(n  2,869)
53.6 (10.75) — 48.5 (11.71)
54.7 (21.3–78.2) — 48.8 (19.3–78.2)
51 1,334 2,788
7) 48.3 (16.81)‡ 32.8 (17.70) 30.3 (17.26)
9.8) 48.3 (13.9–78.2) 32.3 (0.0–80.6) 29.2 (0.0–81.0)
27.7% 25/53, 47.2% 267/1205, 22.2% 659/2,496, 26.4%
0.3% 7/17, 41.2% 361/879, 41.1% 503/1,547, 32.5%
25.9% 17/44, 38.6% 222/1090, 20.4% 547/2,267, 24.1%
(870) 72 18.3 (30) 93 31.2 (1005) 91 39.54 (1,941)
(458) 2.6 4.19 (9) 1.0 1.96 (584) 1.1 2.03 (1,066)
(559) 13.9 3.15 (27) 10.0 2.80 (777) 10.9 3.32 (1,393)
tural history time period (i.e., before the start of enzyme replacement therapy). Percentages were
iagnosis was not available for all patients. Normal values were defined as: left ventricular posterior
ein/urinary creatinine ratio1 g/g. Hypertension was defined as having either ameasured systolic
tension on the case report form. Hypercholesterolemia was defined as having either a measured
al history of hypercholesterolemia on the case report form. Laboratory parameter values included
the natural history period for patients who did not experience CV events. *p 0.001 for men who
nt versus men who did not have CV events, by Student t test. ‡p  0.001 for women who had CV
yocardial infarction, or cardiac-related death) during 6 age categories are
ta are from patients who had not been treated with enzyme replacement therapysistry
n With
V Even
 1,3
—
—
1,320
(15.6
(0.0–7
156,
37, 2
057,
47.5
1.93
3.51
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CV Events in Fabry Disease March 1, 2011:1093–9Hg) at the time of their first CV event. At the time of their
first CV event, 93% of men and 78% of women had LVH;
56% of men and 58% of women had hypertension at that
time. Approximately one-third of the patients with LVH
exhibited LVH in the absence of hypertension (25% of men
and 10% of women, among the 40 patients who had both
types of data available). A substantial proportion of patients
had serious renal dysfunction at the time of their first CV
event, including stage 3 or worse chronic kidney disease and
proteinuria. A higher percentage of men exhibited renal
abnormalities, compared with women, among patients for
whom renal data were available (Fig. 2).
Incidence Rates of CV Events in Fabry Registry PatientsTable 2 Incidence Rates of CV Events in Fabry Registry Patien
0 to <25 25 to <35
Men
Patients ever in age category (n) 1,424 1,003
Patients with CV events, n (%) 5 (0.35) 8 (0.80)
Person-yrs of follow-up time 31,862 8,654
Incidence rate* 0.16 0.92
95% CI for incidence rate 0.1–0.4 0.4–1.8
Women
Patients ever in age category (n) 1,445 1,119
Patients with CV events, n (%) 1 (0.07) 1 (0.09)
Person-yrs of follow-up time 33,306 10,088
Incidence rate* 0.03 0.10
95% CI for incidence rate 0.0–0.2 0.0–0.6
For Fabry Registry patients who experienced a cardiovascular (CV) event, person-years of follow-up w
patients who did not experience CV events, person-years of follow-up were defined as the last ava
multiple age categories, on the basis of their age at the last follow-up visit. *Incidence rate data
CI  confidence interval.
Figure 2 Cardiac and Renal Abnormalities Among Fabry Regist
Percentages were calculated on the basis of the number of patients who had card
(CV) event. Clinical assessments designated as “abnormal” included: LVH  left v
130 mm Hg or diastolic blood pressure 80 mm Hg; chronic kidney disease (CK
teinuria  urinary protein/urinary creatinine ratio 1 g/g. Numbers above the barThe majority of patients had ejection fraction and PR
intervals within the normal range at the time of their first
CV event, among those for whom data were available.
Thirteen of 15 men (87%) and 12 of 19 women (63%) had
PR intervals within the normal range at the time of their
first CV event (defined as PR interval 120 to 200 ms).
Twenty-one of 28 men (75%) and 22 of 25 women (88%)
had ejection fractions within the normal range at the time of
their first CV event (defined as estimated ejection fraction
55%).
The lower portion of Table 1 shows the distribution of
arious potential risk factors among Fabry Registry pa-
e Categories (yrs)
<45 45 to <55 55 to <65 >65 All Ages
8 356 109 21 1,424
.97) 39 (10.96) 7 (6.42) 3 (14.29) 83 (5.83)
7 2,199 495 115 48,631
6 17.74 14.14 26.18 1.71
6.0 12.6–24.2 5.7–29.1 5.4–76.5 1.4–2.1
2 590 312 90 1,445
.78) 19 (3.22) 20 (6.41) 6 (6.67) 54 (3.74)
3 4,420 1,806 522 57,575
4 4.30 11.08 11.49 0.94
1.9 2.6–6.7 6.8–17.1 4.2–25.0 0.7–1.2
fined as the number of years from birth to the date of the first recorded CV event. For Fabry Registry
ollow-up date during the natural history period. Patients over the age of 25 years are included in
ressed as number of first CV events/1,000 person-years of follow-up time.
tients Who Experienced CV Events
renal data available within  12 months of the date of their first cardiovascular
ular posterior wall thickness 12 mm; hypertension  systolic blood pressure
age 3 or worse  estimated glomerular filtration rate 60 ml/min/1.73 m2; pro-
the number of patients with abnormal cardiac or renal values in each group.ts
Ag
35 to
70
21 (2
5,30
3.9
2.4–
89
7 (0
7,43
0.9
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March 1, 2011:1093–9 CV Events in Fabry Diseasetients who experienced CV events and in those who did
not. As in the general population, patients with Fabry
disease who had CV events were more likely to have risk
factors like hypertension, increased left ventricular pos-
terior wall thickness, a history of smoking, and renal
dysfunction, compared with Fabry patients who did not
have CV events.
In Table 3, results of logistic regression analyses of these
factors are shown as ORs expressing the association of each
risk factor with the occurrence of CV events. Univariate
analyses suggested that LVH, hypertension, older age at
diagnosis, hypercholesterolemia (in men), a history of
smoking, and renal dysfunction were associated with the
occurrence of CV events (Table 3). A stepwise selection of
covariates from the univariate analyses identified LVH and
hypertension as the factors most strongly associated with the
occurrence of CV events in each sex. Compared with
patients who did not report hypertension, men with hyper-
tension had a nearly 8-fold increase in the risk of experi-
encing a CV event (OR: 7.8, 95% CI: 2.1 to 28.6, p 
0.0019), and women with hypertension had a 4.5-fold risk
of experiencing a CV event (OR: 4.5, 95% CI: 1.6 to 12.3,
p  0.0037). Left ventricular hypertrophy also significantly
increased the odds of experiencing a CV event in the
multivariate model. Compared with patients who did not
have LVH, men with LVH were nearly 5 times more likely
to experience a CV event (OR: 4.8, 95% CI: 1.0 to 22.2,
p 0.0463), and women with LVH were more than 8 times
more likely to experience a CV event (OR: 8.2, 95% CI: 2.6
to 26.0, p  0.0003). Other parameters that seemed to be
ssociated with CV events in univariate analyses did not
Univariate and Multivariate Analyses of Parameters Related to theTable 3 Univariate and Multivariate Analyses of Parameters Re
Univ
n (Events/No Even
Men
Hypertension (sBP 130 mm Hg or dBP 80 mm Hg
or reported history)
1,239 (83/1,156
LVH (left ventricular posterior wall thickness 12 mm) 590 (31/559)
Older age at Fabry diagnosis (40 yrs) 1,403 (83/1,320
Hypercholesterolemia (total cholesterol 20 mg/dl or
LDL cholesterol 130 mg/dl)
651 (14/637)
Smoking (reported history) 1,133 (76/1,057
Low eGFR (60 ml/min/1.73 m2) 909 (39/870)
Women
Hypertension (sBP 130 mm Hg or dBP 80 mm Hg
or reported history)
1,258 (53/1,205
LVH (left ventricular posterior wall thickness 12 mm) 805 (28/777)
Older age at Fabry diagnosis (40 yrs) 1,385 (51/1,334
Hypercholesterolemia (total cholesterol 20 mg/dl or
LDL cholesterol 130 mg/dl)
896 (17/879)
Smoking (reported history) 1,134 (44/1,090
Low eGFR (60 ml/min/1.73 m2) 1,038 (33/1,005
n (events/no events) represents the total number of patients for whom each type of data were ava
followed by the number of these patients who did not have a CV event. *p  0.0001; †p  0.05;CI  confidence interval; dBP  diastolic blood pressure; eGFR  glomerular filtration rate; LDL  lo
ressure.emerge as significant risk factors in the stepwise selection of
covariates for the multivariate model, in either sex.
The occurrence of other significant clinical events among
this cohort was also analyzed. Twenty-five of 83 men (30%)
and 3 of 54 women (5.6%) who had CV events also
experienced a renal event (defined as renal transplant or
chronic dialysis). Nine of 83 men who had CV events (11%)
and 7 of 54 women who had CV events (13%) also
experienced a stroke. The majority of patients who had CV
events experienced a CV event as their first and/or only
major clinical event during the natural history period (89%
of men and 94% of women). Two of the 137 patients who
experienced CV events were reported to have died: 1 man
who had previously experienced HF, and 1 woman who had
previously experienced MI.
In addition to major CV events (HF, MI, death),
arrhythmias were reported by 281 of 2,869 patients (10%)
during the natural history period (169 men and 112
women), although most of these patients did not have an
arrhythmia type specified in their case report forms. Among
those for whom this information was available, 74% re-
ported atrial arrhythmias.
Discussion
We evaluated data obtained during the natural history
period (i.e., before any ERT or from patients who never
received therapy) in 2,869 Fabry Registry patients. One
hundred thirty-seven patients (83 men and 54 women)
experienced major CV events (i.e., MI, HF, or cardiac-
related death) before any exposure to ERT. Although it is
rrence of CV Eventsto the Occurrence of CV Events
Analyses Multivariate Analyses
OR (95% CI) n (Events/No Events) OR (95% CI)
6.82 (4.14–11.21)* 447 (19/428) 7.81 (2.14–26.56)†
12.05 (3.62–40.1)* 447 (19/428) 4.77 (1.03–22.22)†
3.92 (2.50–6.15)* — —
2.95 (1.01–8.66)† — —
2.31 (1.44–3.71)† — —
2.33 (1.22–4.45)† — —
4.95 (2.81–8.69)* 677 (22/650) 4.47 (1.63–12.27)†
11.17 (4.47–27.96)* 677 (22/650) 8.23 (2.61–26.01)†
4.22 (2.28–7.78)* — —
1.00 (0.38–2.66)‡ — —
2.46 (1.32–4.60)† — —
3.85 (1.78–8.32)* — —
with the numbers in parentheses representing the number of these patients who had a CV event,
tatistically significant by the Wald test.Occulated
ariate
ts)
)
)
)
)
)
)
)
ilable,
‡not sw-density lipoprotein; LVH  left ventricular hypertrophy; OR  odds ratio; sBP  systolic blood
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CV Events in Fabry Disease March 1, 2011:1093–9well-known that Fabry patients have a high risk of CV
events, this is the first study to systematically analyze the
rates and risk factors associated with such events in a large
cohort of patients with Fabry disease. Not unexpectedly, the
incidence rate of CV events was higher among men than
women, because men generally experience higher pen-
etrance and more severe manifestations of X-linked disor-
ders (14). During the natural history period, 3.5% of men
and 2.7% of women experienced HF, whereas 2.7% of men
and 1.5% of women experienced MI. A recent retrospective
chart review of 447 patients with Fabry disease reported very
similar percentages of these events in untreated Fabry
Registry patients (4).
This cohort of patients first experienced CV events at a
mean age of 45 years in men and 54 years in women.
Multivariate analyses indicated that the 2 risk factors most
strongly associated with CV events in both sexes were
hypertension and LVH. In fact, 86% of patients had LVH
and 57% of patients had hypertension at the time of their
first CV event, among those for whom such data were
available. Left ventricular hypertrophy, myocardial fibrosis,
and diminished regional left ventricular function have been
identified as key markers of advanced Fabry cardiomyopathy
(15). Although patients who had CV events were diagnosed
at an older age than patients who did not have events, age
at diagnosis was not a significant predictor of CV events
in a stepwise selection of covariates. Key risk factors,
including hypertension and LVH, would be expected to
worsen with age in both Fabry and non-Fabry patients.
The findings suggest that these parameters, particularly
hypertension, should be closely monitored in Fabry
patients and treated appropriately (16); untreated hyper-
tension is known to lead to various types of more serious
CV disease, including LVH (17).
The Fabry Registry also collects data on renal events (i.e.,
kidney transplants or chronic dialysis) and cerebrovascular
events (i.e., strokes). The majority of patients in this cohort
experienced a CV event as their first and/or only major clinical
event during the natural history period (89% of men and 94%
of women). However, a substantial proportion of patients
exhibited chronic kidney disease stage 3 or worse and/or
proteinuria at the time of their first CV event. Because renal
disease itself can cause or exacerbate heart disease (18), renal
dysfunction might also play an indirect role in the development
of hypertension and Fabry cardiomyopathy.
Studies on patients with Fabry cardiomyopathy have
demonstrated a significant increase in left ventricular mass
and posterior lateral wall hyperenhancement on cardiac
magnetic resonance imaging that correlates with fibrosis
(19–21). As with other cardiomyopathies, this increase in
left ventricular mass and myocardial fibrosis might be the
substrate for cardiac events (22–24).
Enzyme replacement therapy has been shown to reduce
left ventricular mass and improve myocardial function in
some patients with Fabry disease (25–28); however, it seemsto be more effective in patients who are in the early stages of
Fabry cardiomyopathy without evidence of myocardial fi-
brosis (29). Similarly, in terms of renal function, ERT has
been shown to be most beneficial when initiated before the
onset of advanced renal disease (30–32). Given the natural
history of CV events in the patient population evaluated,
future studies should focus on the effect of ERT on CV
events. Fabry patients might benefit from general therapies
used to control cardiac and renal disease, in addition to
ERT, such as the use of angiotensin-converting enzyme
inhibitors and/or angiotensin receptor blockers to control
urinary protein excretion (33).
Study limitations. Observational data reported to regis-
tries are subject to various limitations. For example, a
schedule of recommended clinical assessments is provided,
but treating physicians determine the actual frequency of
assessments according to individual patient needs. Similarly,
the Fabry Registry case report form provides a standardized
definition of clinical events; however, individual physicians
are responsible for reporting their patient data. It is also
important to note that not all patients who had CV events
during the natural history period had complete sets of
clinical data reported, which limited the number of patients
who could be included in the logistic regression models of
associations between CV events and specific risk factors.
The numbers of patients who had CV events in the
univariate analyses ranged from 14 to 83 for men and from
17 to 53 for women. The multivariate analyses included data
from 19 men and 22 women who had CV events and who
also had both echocardiographic and blood pressure data
available. These numbers are relatively small compared with
the total number of patients in this cohort who had CV
events (83 men and 53 women). Therefore, these patients
might not be representative of the overall population of
Fabry patients who experience CV events. In addition, these
are cross-sectional analyses of patients at different ages and
with a wide range of disease severity, and the temporal
relationship between clinical or medical history characteris-
tics (risk factors) and CV events was not established.
Conclusions
Patients with Fabry disease, particularly those with hyper-
tension and/or LVH, have a high risk of experiencing HF
and MI at a relatively young age. Many patients also
experience various types of arrhythmias. The cardiac man-
ifestations of Fabry disease are consistent with other forms
of CV disease, which makes it difficult to identify the
disease solely on the basis of cardiac assessments. The
medical community in general, especially cardiologists,
should be aware of Fabry disease as a possible cause of
cardiac dysfunction. Earlier diagnosis of these patients,
before the onset of end organ failure, will allow for prompt
initiation of appropriate treatment.
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